Rezzayo (Rezafungin Acetate) Patent Expiration, LOE Window & CMS Spending

Rezzayo (Rezafungin Acetate) by Mundipharma Gmbh: FDA Orange Book core substance LOE 2038-07-14, 0 AB generics, $448K 2024 CMS Part D & Medicaid spend, and $1,950 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorMundipharma Gmbh
FDA Application & PathwayN217417 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2038-07-14
Last Listed Patent or Exclusivity Date2038-07-14
Orange Book Patents (*PED Extensions)7 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$448K
2024 Medicare Part D Spend$161K
2024 Medicaid Spend$287K
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($1,950 intro WAC)